Clinicopathological profile of peritoneal tuberculosis and a new scoring model for predicting mortality: an international ID-IRI study.

Abstract

Existing literature about peritoneal tuberculosis (TBP) is relatively insufficient. The majority of reports are from a single center and do not assess predictive factors for mortality. In this international study, we investigated the clinicopathological characteristics of a large series of patients with TBP and determined the key features associated with mortality. TBP patients detected between 2010 and 2022 in 38 medical centers in 13 countries were included in this retrospective cohort. Participating physicians filled out an online questionnaire to report study data. In this study, 208 patients with TBP were included. Mean age of TBP cases was 41.4 ± 17.5 years. One hundred six patients (50.9%) were females. Nineteen patients (9.1%) had HIV infection, 45 (21.6%) had diabetes mellitus, 30 (14.4%) had chronic renal failure, 12 (5.7%) had cirrhosis, 7 (3.3%) had malignancy, and 21 (10.1%) had a history of immunosuppressive medication use. A total of 34 (16.3%) patients died and death was attributable to TBP in all cases. A pioneer mortality predicting model was established and HIV positivity, cirrhosis, abdominal pain, weakness, nausea and vomiting, ascites, isolation of Mycobacterium tuberculosis in peritoneal biopsy samples, TB relapse, advanced age, high serum creatinine and ALT levels, and decreased duration of isoniazid use were significantly related with mortality (p < 0.05). This is the first international study on TBP and is the largest case series to date. We suggest that using the mortality predicting model will allow early identification of high-risk patients likely to die of TBP.

• Authors: Alpaslan Tanoglu, Hakan Erdem, Jon S Friedland, Handan Ankaralı, Jose Fernando Garcia-Goez, Ayse Albayrak, Amani El-Kholy, Sevil Alkan Ceviker, Fatma Amer, Serpil Erol, Ilad Alavi Darazam, Mohammad Mahdi Rabiei, Muhammad Zeeshan Sarwar, Misbah Zeb, Hassan Nawaz, Mehmet Resat Ceylan, Roxana Cernat, Meltem Tasbakan, Folusakin Ayoade, Yvon Ruch, Elif Tükenmez Tigen, Goffredo Angioni, Dhanji P Rajani, Nasim Akhtar, Serkan Surme, Gonul Sengoz, Gulden Eser Karlıdag, Andrea Marino, Rezaul Karim Ripon, Yasemin Çağ, Özlem Aydın, Yasemin Akkoyunlu, Derya Seyman, Kumar Angamuthu, Antonio Cascio, Corneliu Petru Popescu, Fatma Sirmatel, Esma Eren, Razi Even Dar, Foday Usman Munu, Esra Guzel Tanoglu, Esteban Echeverry, Juan Diego Velez, Cumhur Artuk, Safak Ozer Balin, Nirav Pandya, Aysegul Erdem, Emine Kübra Dindar Demiray, Adalet Aypak
• Journal: European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology (Eur J Clin Microbiol Infect Dis) Vol. 42 Issue 8 Pg. 981-992 (Aug 2023) ISSN: 1435-4373 [Electronic] Germany
• PMID: 37318601 (Publication Type: Journal Article)
• Copyright: © 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Chemical References

• Isoniazid
• Antitubercular Agents

Topics

• Female
• Humans
• Young Adult
• Adult
• Middle Aged
• Male
• HIV Infections (complications, drug therapy)
• Retrospective Studies
• Mycobacterium tuberculosis
• Isoniazid
• Liver Cirrhosis
• Tuberculosis
• Antitubercular Agents (therapeutic use)